loxoprofen has been researched along with Cholera Infantum in 5 studies
loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding." | 8.02 | Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan. ( Kamae, I; Karasawa, Y; Murata, T; Nozawa, K; Sakamoto, C; Soen, S; Zeniya, S, 2021) |
| "Loxoprofen (LOX) is a nonsteroidal anti-inflammatory drug (NSAID)." | 6.90 | Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial. ( Chen, Z; Hu, S; Li, Z; Lin, J; Shao, Z; Shi, Y; Wang, G; Xiao, W; Zhang, Z; Zhao, D; Zheng, Y, 2019) |
| "The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding." | 4.02 | Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan. ( Kamae, I; Karasawa, Y; Murata, T; Nozawa, K; Sakamoto, C; Soen, S; Zeniya, S, 2021) |
| "Loxoprofen (LOX) is a nonsteroidal anti-inflammatory drug (NSAID)." | 2.90 | Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial. ( Chen, Z; Hu, S; Li, Z; Lin, J; Shao, Z; Shi, Y; Wang, G; Xiao, W; Zhang, Z; Zhao, D; Zheng, Y, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, T | 1 |
| Hazama, K | 1 |
| Kosuge, Y | 1 |
| Suzuki, S | 1 |
| Ootsuka, S | 1 |
| Karasawa, Y | 1 |
| Kamae, I | 1 |
| Nozawa, K | 1 |
| Zeniya, S | 1 |
| Murata, T | 1 |
| Soen, S | 1 |
| Sakamoto, C | 1 |
| Lai, EC | 1 |
| Shin, JY | 1 |
| Kubota, K | 1 |
| Man, KKC | 1 |
| Park, BJ | 1 |
| Pratt, N | 1 |
| Roughead, EE | 1 |
| Wong, ICK | 1 |
| Kao Yang, YH | 1 |
| Setoguchi, S | 1 |
| Zhao, D | 1 |
| Chen, Z | 1 |
| Hu, S | 1 |
| Lin, J | 1 |
| Shao, Z | 1 |
| Wang, G | 1 |
| Xiao, W | 1 |
| Zheng, Y | 1 |
| Zhang, Z | 1 |
| Shi, Y | 1 |
| Li, Z | 1 |
| Yanagawa, A | 1 |
| Fukumura, T | 1 |
| Matsui, H | 1 |
| Uemura, H | 1 |
| Endo, T | 1 |
| Nakagawa, T | 1 |
| Mizushima, Y | 1 |
2 trials available for loxoprofen and Cholera Infantum
| Article | Year |
|---|---|
Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; China; Double-Blind Meth | 2019 |
Possible mechanisms of gastroduodenal mucosal damage in volunteers treated with nonsteroidal antiinflammatory drugs--the usefulness of prodrugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Digestive System; Dinoprostone; Double-B | 1992 |
3 other studies available for loxoprofen and Cholera Infantum
| Article | Year |
|---|---|
Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER.
Topics: Adverse Drug Reaction Reporting Systems; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Databases | 2022 |
Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan.
Topics: Aged; Aged, 80 and over; Celecoxib; Chronic Pain; Computer Simulation; Cost Savings; Cost-Benefit An | 2021 |
Comparative safety of NSAIDs for gastrointestinal events in Asia-Pacific populations: A multi-database, international cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Databases, F | 2018 |